Endogenex Names Former Medtronic VP Krissy Wright as CFO

Endogenex, a clinical-stage medical device company, has appointed Krissy Wright as its new chief financial officer (CFO). Wright will lead the company’s financial strategy, corporate development initiatives, and operational planning to support Endogenex’s clinical initiatives.

She brings experience from artificial intelligence (AI)-driven heart diagnostics company Cleerly, where she was CFO. Wright also held leadership roles at Medtronic, including VP and GM of Brain Modulation and VP and CFO for the Neuromodulation Operating Unit.

Earlier in her career, Wright spent 11 years at PricewaterhouseCoopers, specializing in audit, assurance, and transaction services.

“I am thrilled to be joining Endogenex at such a pivotal moment in its journey,” said Wright. “The company’s novel approach to addressing type 2 diabetes can potentially transform the lives of millions worldwide. I look forward to leveraging my financial expertise to support the team in advancing this groundbreaking therapy and achieving our mission of delivering meaningful, scalable healthcare solutions.”

Endogenex’s ReCET is a novel, endoscopic, outpatient procedure that targets underlying cellular abnormalities in the duodenum that contribute to type 2 diabetes development and progression. It applies highly controlled, non-thermal pulsed electric fields to begin the body’s natural regenerative process to restore proper cellular signaling from the duodenum and improve glycemic control.

The ReCET procedure is currently being evaluated in global pre-commercialization trials assessing its safety and efficacy in adults with type 2 diabetes who are inadequately controlled despite the use of insulin and non-insulin medications. The ReCET Procedure has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) to treat type 2 diabetes in adult patients inadequately controlled by glucose-lowering medications.